Adobe develops new technology in Basel
The US-based company Adobe is developing a technology in Basel that will make it possible to display content on screens more quickly. Basel is a central R&D location for the American software provider, says Christoph Kull, head of Central Europe at Adobe.
Computer chip (Img: stephen4/Pixabay)
Basel plays an important role for Adobe. “Basel is a central location for our research and development and is Europe’s largest training center for Adobe Experience Manager,” Christoph Kull, Vice President and Managing Director Central Europe at Adobe, is quoted in an article in the Sunday newspaper NZZ am Sonntag. “So many of today’s customer experiences also include architecture and innovation developed in Basel”.
The US software company is accelerating the development of its Adobe Experience Manager (AEM) from its offices in Basel, a program that allows users to centrally manage their data volumes and adapt them to their end devices. The global support center for critical AEM application cases also happens to be located in Basel, according to Florian Schaulin, manager of the Basel offices. The company is also currently working on a technology that will make it possible to display individual content on screens more quickly.
Adobe has been present in Basel since 2010, when it acquired Day Software, which was founded in 1993. Adobe’s employees come from prominent institutions including the Federal Institute of Technology in Zurich and the University of Basel. Adobe also supports the university financially and awards doctoral theses. In addition, Adobe offers four apprenticeships in Basel.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More